Group Leader, MRC Toxicology Unit, Cambridge; expertise in characterisation of genetic disorders of immune function (J. Exp. Med., 2019; Nature, 2020) and studies of immune response to SARS-CoV2 in immunocompromised patients (Nature Comms. 2020).
Wellcome Principal Research Fellow, Wellcome-MRC Institute of Metabolic Science, Cambridge; international leader in genetic (Cell 2019), molecular and physiological mechanisms involved in obesity (Nature Medicine 2018, NEJM 2021). Experience of managing multi-disciplinary teams, large collaborative projects and of contributing to clinical guidelines and policy.
Clinical Lecturer in Metabolic Medicine, Addenbrooke’s Hospital, Cambridge, track record of physiological studies in metabolism and endocrinology (Cell 2019, Nature Communications 2016, 2019) most recently as a Wellcome Postdoctoral Clinical Fellow. Developing an independent programme of research on obesity and immunity including involvement in the CovBOOST trial as an Associate PI.
MRC Clinician Scientist and Group Leader, Cambridge Institute of Therapeutic Immunology & Infectious Disease studying host-virus interactions in HIV (Cell Reports 2019) and SARS-CoV-2 (Elife 2020 and 2021; Science 2020).
Group Leader, Babraham Institute; expertise in studying immune response to vaccination, including large scale human vaccination studies (J Exp Med 2019, Sci Transl Med 2020) and pre-clinical immunogenicity work on COVID-19 vaccines (Med NY 2021).
Professor of Bariatric and Metabolic Surgery at KCH. PI/Co-PI of seminal studies of metabolic surgery for type 2 diabetes (NEJM 2012, Lancet 2021). Development of international clinical guidelines (Diabetes Care 2016 and Nature 2016).Currently PI of CoviDIAB, a global Registry of Covid-19 related diabetes (NEJM 2020).